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MAINTENANCE OF WARFARIN ANTICOAGULATION FOR PATIENTS UNDERGOING 
VITREORETINAL SURGERY 
BY Pouya N. Dayani MD, AND M. Gilbert Grand MD* 
ABSTRACT 
Purpose:  The purpose of this study was to evaluate the risk of hemorrhagic complications associated with vitreoretinal surgery in 
patients in whom warfarin therapy was continued throughout the surgical period. 
Methods:  A review of 1,737 consecutive charts of patients undergoing pars plana vitrectomy was conducted.  Inclusion criteria 
included patients on warfarin therapy whose international normalized ratio (INR) was elevated above normal on the day of 
vitreoretinal surgery.  The occurrence of intraoperative and postoperative hemorrhagic complications was documented.  
Results:  The retrospective review detected 54 patients who underwent 57 vitreoretinal surgical procedures while on warfarin therapy.  
Group S consisted of patients whose INR ranged from 1.2 to 1.49, values that were considered to be subtherapeutic.  Group B had 
INR values ranging from 1.5 to 1.99, values that were considered to be borderline therapeutic.  Group T had INRs ranging from 2.0 to 
2.49, values that were considered therapeutic.  Group HT had INRs of 2.5 or greater, values that were considered highly therapeutic.   
No patients experienced anesthesia-related or intraoperative hemorrhagic complications.  Four procedures (7.0%) were complicated by 
postoperative hemorrhage.  Two of 26 eyes (7.7%) in group S and two of 12 eyes (16.7%) in group HT experienced postoperative 
hemorrhages.  All hemorrhagic complications cleared without additional therapy. 
Conclusions:  Our findings suggest that many patients may safely undergo vitreoretinal surgery while maintaining therapeutic levels 
of warfarin anticoagulation.  We found no intraoperative hemorrhagic complications.  Those hemorrhagic complications that occurred 
postoperatively resolved spontaneously without persistent visual sequelae or the need for supplemental surgery. 
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INTRODUCTION 
Warfarin (Coumadin) anticoagulation is generally used for the management of potentially life-threatening diseases.  The effect of 
warfarin anticoagulation on vitreoretinal surgery is largely unknown.  Maintenance of anticoagulation during surgery may be 
associated with an increased risk of intraoperative or postoperative hemorrhage.  Yet, discontinuation may subject patients to the risk 
of systemic complications such as embolic disease or cerebrovascular accident.  Therefore, decisions regarding maintenance, 
modification, or perioperative discontinuation of anticoagulation therapy pose a significant dilemma for the ophthalmic surgeon.  The 
purpose of this study is to provide further information regarding the results of vitreoretinal surgery in patients in whom warfarin 
therapy was continued throughout the surgical period. 
METHODS 
Approval was granted by the Washington University Medical Center Human Studies Committee for a retrospective review of patient 
charts. The charts of 1,737 consecutive patients who underwent pars plana vitrectomy performed by surgeons of the Barnes Retina 
Institute during the period of January 1, 2004, through December 20, 2005, were reviewed.  Inclusion criteria included those patients 
on warfarin therapy whose international normalized ratio (INR) and prothrombin time (PT) were elevated above normal values on the 
day of vitreoretinal surgery.  Surgical procedures that occurred prior to 2004 on the identified patients were also included if patients 
had an elevated INR value at the time of that procedure.  Concomitant use of other anticoagulants, such as clopidogrel (Plavix) and 
aspirin, was noted.  Data collected included age; gender; the etiologic agent for which warfarin anticoagulation therapy was employed; 
the preoperative vitreoretinal diagnosis for which surgery was indicated; the type of surgery, including vitreous technique and the use 
of additional surgical techniques, such as scleral buckling; and the method of anesthesia subdivided into general anesthesia or local 
infiltration with monitored anesthesia care (MAC).  Preoperative and postoperative nonstandardized Snellen visual acuity was 
determined.  The INR at the time of surgery was collected, and PT and partial thromboplastin time (PTT) were recorded when 
available.  The occurrence of intraoperative and postoperative hemorrhagic complications, defined as bleeding that occurred within 1 
month following surgery, was documented.   
RESULTS 
The retrospective review of records detected 54 patients who underwent 57 vitreoretinal surgical procedures while on warfarin 
anticoagulation therapy.  The records of these patients were subdivided into four groups based on the INR values obtained on the day 
of surgery.  Group S consisted of patients whose INR ranged from 1.2 to 1.49, values that were considered to be subtherapeutic.  
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Group B had INRs ranging from 1.5 to 1.99, values that were considered to be borderline therapeutic.  Group T had INRs ranging 
from 2.0 to 2.49, values that were considered therapeutic.  Group HT had INRs of 2.5 or greater, values that were considered highly 
therapeutic. 
GROUP S (SUBTHERAPEUTIC) 
There were 24 patients undergoing 26 vitreoretinal procedures who had a mean INR equal to 1.30 (range, 1.2 to 1.49).  Patients in this 
group had a mean PT of 16.0 seconds (range, 15.0 to 17.5 seconds).  One patient had an abnormal PTT equal to 38.8 seconds (normal, 
35.0).  Patients taking concomitant medications associated with prolonged bleeding included one taking aspirin and two taking 
clopidogrel.  The group included 15 men and nine women with a mean age of 72 years (range, 51 to 93 years) (Table 1). 
 
TABLE 1. HEMORRHAGIC COMPLICATIONS RELATED TO VITREORETINAL SURGERY: 
GROUP S (SUBTHERAPEUTIC)* 











76 1.20  Atrial 
fibrillation 
VH – PDR PPV None 
75 1.50  Unknown ERM PPV, MP, 
SOR 
None 
55 1.20  Atrial 
fibrillation 
ERM PPV, MP None 
79 1.22  Atrial 
fibrillation 
ERM PPV, MP None 
73 1.28  Atrial 
fibrillation 
MH PPV None 
74 1.28  Atrial 
fibrillation 
MH PPV, MP None 
69 1.36  Atrial 
fibrillation 
MH PPV, MP None 











68 1.30  Unknown VH – retinal 
tear 
PPV, MP None 
78 1.30  Atrial 
fibrillation 
ERM PPV, MP None 
75 1.30  Atrial 
fibrillation 
VH, PDR PPV None 
75 1.48  DVT/PE MH PPV, MP None 
74 1.30  Atrial 
fibrillation 
MH PPV, MP None 
53 1.30  CABG TRD, PDR PPV, MP None 
79 1.28  Atrial 
fibrillation 






88 1.47  Atrial 
fibrillation 




78 1.29 38.8 Unspecified 
arrhythmia 
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TABLE 1 (CONTINUED). HEMORRHAGIC COMPLICATIONS RELATED TO 
VITREORETINAL SURGERY: GROUP S (SUBTHERAPEUTIC)* 
















79 1.25 Plavix Atrial 
fibrillation 
Sub heme – 
AMD 
PPV, SPA None 
56 1.24  Atrial 
fibrillation 
VH – RD PPV, SB None 
57 1.41 Aspirin Prosthetic 
valves 
VH - PDR PPV, MP Dense VH‡ 
Recurrent 
VH§ 
72 1.30  Atrial 
fibrillation 
VH – CRVO PPV, MP None 
56 1.30  Atrial 
fibrillation 
ERM PPV, MP None 
78 1.20  Prosthetic 
valves 
ERM PPV, MP None 
51 1.20  DVT VH – PDR PPV, MP None 
AMD = age-related macular degeneration; CABG = coronary artery bypass graft; Cryo = cryoretinopexy; 
CRVO = central retinal vein occlusion; DVT = deep vein thrombosis; ERM = epiretinal membrane; FNA 
BX = fine-needle biopsy; INR = international normalized ratio; MH = macular hole; MP = membrane 
peel; PDR = proliferative diabetic retinopathy; PE = pulmonary embolism; PPV = pars plana vitrectomy; 
PTT = partial thromboplastin time; RD = retinal detachment; SB = scleral buckle; SO = silicone oil; SOR 
= silicone oil removal; SPA = subretinal tissue plasminogen activator; Sub heme = subretinal hemorrhage; 
TRD = traction retinal detachment; VH = vitreous hemorrhage. 
*INR value, 1.2 to 1.49. 
 †Recurrent VH on postoperative day 1, no additional follow-up. 
‡Dense VH at postoperative week 2; cleared spontaneously. 
§Recurrent VH at week 7 postsurgery; cleared to 20/80. 
 
The underlying systemic etiologies requiring warfarin anticoagulation included atrial fibrillation (14), cardiac valve surgery (3), 
deep vein thrombosis (2), coronary artery disease status post bypass (1), unspecified cardiac arrhythmia (1), and unknown (3).   
The preoperative vitreoretinal diagnoses included vitreous hemorrhage (8), of which four were attributed to proliferative diabetic 
retinopathy, two had an associated tear and retinal detachment, one had associated central retinal vein occlusion, and one had 
hemorrhage secondary to exudative age-related macular degeneration.  The remaining surgical indications included epiretinal 
membrane (6), macular hole (5), subretinal hemorrhage associated with age-related macular degeneration (3), chronic vitritis (2), 
retinal detachment (1), and diabetic retinopathy with retinal detachment (1). 
Twenty-five eyes underwent pars plana vitrectomy.  Of these, 16 eyes had vitrectomy associated with membrane peeling, one had 
an additional scleral buckling procedure, and one underwent administration of subretinal tissue-type plasminogen activator (tPA).  
One eye underwent a combination of fine-needle biopsy aspiration as well as vitrectomy.  Five procedures were managed using 
general anesthesia and 21 with local infiltration of anesthesia and MAC.  A standard three-port 20-gauge pars plana vitrectomy was 
used for 24 eyes, and 25-gauge vitrectomy was used for two.  Preoperative visual acuity ranged from 20/40 to light perception, and 
postoperative acuity ranged from 20/25 to hand motions.  Preoperative and postoperative distribution of acuities is shown in Figure 1. 
There were no intraoperative or anesthetic complications.  One patient had a recurrent vitreous hemorrhage on the first 
postoperative day.  No additional follow-up was available.  This patient’s INR was 1.28 at the time of surgery for an extramacular 
subretinal hematoma with overlying vitreous hemorrhage.  The surgical procedure included fine-needle biopsy aspiration as well as 
vitrectomy.  A second patient with an INR value of 1.41 had a recurrent vitreous hemorrhage 2 weeks following surgery for 
proliferative diabetic retinopathy with vitreous hemorrhage.  The surgical procedure performed was vitrectomy with membrane 
peeling, peripheral cryopexy, and endolaser.  The hemorrhage spontaneously cleared; however, at 7 weeks postoperatively, this patient 
experienced a second vitreous hemorrhage, which also spontaneously cleared  (Table 1). 
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Visual results following vitreoretinal surgery in patients on warfarin therapy. International normalized ratio indicates 
subtherapeutic or borderline therapeutic level of anticoagulation. CF = counting fingers, HM = hand motions, NLP = 
no light perception, VA = visual acuity.  
 
GROUP B (BORDERLINE THERAPEUTIC) 
There were 11 patients undergoing 12 vitreoretinal procedures who had a mean INR equal to 1.7 (range, 1.5 to 1.99).  Patients in this 
group had a mean PT of 19.9 seconds (range, 17.7 to 21.9). 
Four patients also had an abnormal PTT with values ranging from 35.6 to 46.8 seconds (normal, <35.0).  Concomitant medications 
included aspirin in one patient and clopidogrel in one.  The group included nine men and two women with a mean age of 73 years 
(range, 41 to 85 years) (Table 2). 
 
TABLE 2. HEMORRHAGIC COMPLICATIONS RELATED TO VITREORETINAL 
SURGERY: GROUP B (BORDERLINE THERAPEUTIC)*  
 





















SO removal None 
84 1.70  Unspecified 
arrhythmia 
ERM PPV, MP None 
85 1.77  Atrial 
fibrillation 
RD PPV, SB None 
82 1.74  Unknown RD PPV None 
69 1.80  Atrial 
fibrillation 
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TABLE 2 (CONTINUED). HEMORRHAGIC COMPLICATIONS RELATED TO 
VITREORETINAL SURGERY: GROUP B (BORDERLINE THERAPEUTIC)*  











69 1.80  Atrial 
fibrillation 
TRD PPV, PPL, 
MP, SB, SO 
None 















83 1.77 35.6 DVT/PE VH-PVD PPV None 
75 1.60 37.1 DVT/PE ERM PPV, MP None 
85 1.70 Aspirin CABG RD PPV None 
CABG = coronary artery bypass graft; DVT = deep vein thrombosis; ERM = epiretinal membrane; INR = 
international normalized ratio; MP = membrane peel; PE =  pulmonary embolism; PPL = pars plana 
lensectomy; PPV = pars plana vitrectomy; PTT = partial thromboplastin time; PVD = posterior vitreous 
detachment; RD = retinal detachment; SB = scleral buckle; SO = silicone oil;  VH = vitreous hemorrhage; 
Vit = vitreous. 
*INR value, 1.5 to 1.99.  
 
 
The underlying systemic etiologies requiring warfarin anticoagulation included atrial fibrillation (4), cardiac valve surgery (1), 
deep vein thrombosis with pulmonary embolism (2), aortic aneurysms and coronary artery bypass surgery (1), unspecified arrhythmia 
(1), and unknown (2).   
The preoperative vitreoretinal diagnoses included vitreous hemorrhage (1), retinal detachment (6), epiretinal membrane (2), 
chronic vitritis (1), tractional retinal detachment (1), and retained silicone oil (1).  Eleven eyes underwent pars plana vitrectomy 
procedures; four were associated with membrane peeling, two with scleral buckling, and two with pars plana lensectomy.  One patient 
underwent vitrectomy for silicone oil removal.  General anesthesia was used in four patients, with local infiltration anesthesia (MAC) 
in eight.  Surgical technique involved standard three-port 20-gauge pars plana vitrectomy in 11 procedures and 25-gauge vitrectomy in 
one. 
Preoperative visual acuity ranged from 20/40 to hand motions, and postoperative visual acuity ranged from 20/40 to counting 
fingers.  Distribution of preoperative and postoperative visual acuities is shown in Figure 1. 
There were no anesthetic complications, and no patients in this group developed intraoperative or postoperative hemorrhagic 
complications.  
GROUP T (THERAPEUTIC) 
There were seven patients undergoing a total of seven vitreoretinal procedures, who had a mean INR equal to 2.1 (range, 2.0 to 2.49).  
The mean PT was 24.0 seconds (range, 22.8 to 26.0 seconds).  One patient had an abnormal PTT of 46.1 seconds (normal, <35.0).  
Concomitant medications included aspirin in one patient, celecoxib (Celebrex) in two, and rofecoxib (Vioxx) in one.  The group 
consisted of five males and two females with a mean age of 58 years and a median age of 68 years (range, 8 to 72 years) (Table 3). 
The underlying systemic etiologies requiring warfarin anticoagulation included atrial fibrillation (2), deep vein thrombosis (1), 
heart transplant with a prosthetic valve (1), cardiac valve surgery (1), and unknown (2).  The preoperative vitreoretinal diagnoses 
included retinal detachment (6) and retained silicone oil (1).  The surgical procedure employed was pars plana vitrectomy in six 
patients, with associated membrane peel in five, scleral buckling in four, and lensectomy in one.  One patient underwent silicone oil 
removal by means of pars plana vitrectomy.  The surgical technique involved standard three-port 20-gauge vitrectomy in all patients.  
General anesthesia was used in three patients and local infiltrative anesthesia (MAC) in four.  Preoperative visual acuity ranged from 
20/25 to counting fingers, and postoperative visual acuity ranged from 20/20 to no light perception.  Distribution of preoperative and 
postoperative acuities is shown in Figure 2. 
There were no anesthetic complications, and no patients in this group developed intraoperative or postoperative hemorrhages. 
GROUP HT (HIGHLY THERAPEUTIC) 
Twelve patients who underwent 12 vitreoretinal procedures had a mean INR of 2.8 (range, 2.5 to 3.6).  Patients in this group had a 
mean PT of 29.4 seconds (range, 26.3 to 36.4 seconds).  Six patients had an associated abnormal PTT with values ranging from 40.2 
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to 73.4 seconds.  Concomitant medicines included aspirin in one patient and celecoxib in one.  The group included 10 men and two 
women with a mean age of 67 years (range, 42 to 79 years) (Table 4). 
 
TABLE 3. HEMORRHAGIC COMPLICATIONS RELATED TO VITREORETINAL 
SURGERY: GROUP T (THERAPEUTIC)* 











68 2.00  Unknown RD PPV, MP, 
SO 
None 
72 2.10 Celebrex DVT RD PPV, SB, 
MP 
None 




RD PPV, PPL, 
SB, MP, SO 
None 
54 2.10 46.1; Vioxx Atrial 
fibrillation 
RD PPV, SB, 
MP, SO 
None 
63 2.20 Celebrex Prosthetic 
valves 
SO removal SO removal None 
72 2.40   RD PPV, MP None 
70 2.10 Aspirin Atrial 
fibrillation 
RD PPV, SB None 
DVT = deep vein thrombosis; INR = international normalized ratio; MP = membrane peel; PPL = pars 
plana lensectomy; PPV = pars plana vitrectomy; PTT = partial thromboplastin time; RD = retinal 
detachment;  SB = scleral buckle; SO = silicone oil. 




Visual results following vitreoretinal surgery in patients on warfarin therapy. International normalized ratio indicates 
therapeutic or highly therapeutic levels of anticoagulation. CF = counting fingers, HM = hand motions, NLP = no 
light perception, VA = visual acuity. 
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TABLE 4. HEMORRHAGIC COMPLICATIONS RELATED TO VITREORETINAL SURGERY: 
GROUP HT (HIGHLY THERAPEUTIC)*  











79 2.50  Atrial 
fibrillation 
ERM PPV, MP None 
66 2.50  DVT/PE RD PPV, SB None 









63 2.69 Celebrex Prosthetic 
valves 
RD PPV, SO None 
68 2.70 73.4 DVT/PE RD PPV None 
72 2.70  Atrial 
fibrillation 
VH PPV None 
64 2.68  Prosthetic 
valves 
VH – PDR PPV, MP Recurrent 
VH† 
70 3.60 61.4 DVT/PE VH – PDR PPV None 
42 2.83 48.6 Prosthetic 
valves 
RD SO removal, 
PPV, SO 
None 






PPV, MP None 
69 2.69 55.3 Atrial 
fibrillation 










75 2.53 41.9 Atrial 
fibrillation 
RD PPV None 
DVT = deep vein thrombosis; ERM = epiretinal membrane; INR = international normalized ratio; MP = 
membrane peel; PDR = proliferative diabetic retinopathy; PE = pulmonary embolism; PPV = pars plana 
vitrectomy; PTT = partial thromboplastin time; RD = retinal detachment; SB = scleral buckle; SO = 
silicone oil; VH = vitreous hemorrhage. 
*INR value,  >2.49. 
†Recurrent VH postoperative week 1, resolved without therapy. 
‡VH, hyphema and nasal choroidal detachment on postoperative day 7, cleared spontaneously. 
 
The underlying systemic etiology requiring anticoagulation was atrial fibrillation (5), deep vein thrombosis/pulmonary embolism 
(3), valve replacement surgery (3), and an unspecified arrhythmia (1).  The preoperative vitreoretinal diagnoses included retinal 
detachment in five patients, one of whom had an associated vitreous hemorrhage, and vitreous hemorrhage without retinal detachment 
in four patients, three of whom had proliferative diabetic retinopathy.  One patient with proliferative diabetic retinopathy had iris 
neovascularization with secondary glaucoma and hyphema.  Other diagnoses included epiretinal membrane (1), retained lens 
fragments (1), and macular edema (1).  The surgical procedure performed was pars plana vitrectomy in all 12 patients, with associated 
membrane peeling in three, removal of lens fragments in one, anterior chamber washout in one, and scleral buckling in one.  The 
surgical technique was standard three-port 20-gauge pars plana vitrectomy in 11 patients and 25-gauge vitrectomy in one.  General 
anesthesia was used in one patient, and 11 patients underwent local infiltrative anesthesia (MAC).   
Preoperative visual acuity ranged from 20/20 to light perception, and postoperative visual acuity ranged from 20/25 to counting 
fingers.  Distribution of preoperative and postoperative visual acuities is shown in Figure 2. 
In this group, there were no anesthetic complications, and no patients experienced intraoperative hemorrhagic complications.  
Postoperatively, two patients (17%) were noted to have an intraocular hemorrhage.  One patient with an INR of 2.68 and a normal 
PTT underwent surgery for proliferative retinopathy with vitreous hemorrhage.  This patient had hemorrhage in the inferior vitreous 
cavity at 1 week postoperatively that spontaneously resolved without therapy over the ensuing 2 months.  A second patient with an 
INR value of 2.69 underwent surgery for proliferative diabetic retinopathy with iris neovascularization, hyphema, and vitreous 
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hemorrhage.  This patient had vitreous hemorrhage and hyphema postoperatively.  It was unclear whether this hemorrhage represented 
residual or recurrent bleeding.  A nasal choroidal detachment was also noted on the first postoperative day; however, it was not 
determined whether the detachment was hemorrhagic or serous.  The hyphema, vitreous hemorrhage, and choroidal detachment 
resolved spontaneously without additional treatment.   
DISCUSSION 
Warfarin is an anticoagulant typically used in patients with atrial fibrillation, venous thromboembolism, mechanical or diseased heart 
valves, cardioembolic cerebroischemic events, and acute myocardial infarction.  The anticoagulant effect of warfarin is mediated 
through inhibition of the vitamin K–dependent gamma-carboxylation of coagulation factors II, VII, IX, and X.1,2  The full 
anticoagulant effect of warfarin may be delayed for 36 to 72 hours after administration until the normal clotting factors have been 
cleared from the patient’s circulation.3  Upon initiation of therapy, warfarin can create a biochemical paradox by producing an 
anticoagulant effect due to inhibition of procoagulants, while also producing a potentially thrombogenic effect by impairing the 
synthesis of naturally occurring inhibitors of coagulation, such as proteins C and S.4  Warfarin is strongly protein-bound; any agent 
that also binds to albumin may displace warfarin and increase its biological activity. 
The laboratory test most commonly used to monitor warfarin therapy is the one-stage PT, which is sensitive to reduced activity of 
factors II, VII, and X.  This test utilizes thromboplastin to activate clotting in blood specimens.  There are many different 
commercially available thromboplastins that are typically derived from extracts of lung, brain, or placenta.  Different thromboplastins 
yield varied PT responses to warfarin-induced anticoagulation.  Different makes and models of coagulation analyzers may also affect 
PT values.  Consequently, PT values do not reliably agree between laboratories and are not suitable for defining therapeutic ranges for 
warfarin therapy.  The INR was developed to standardize PT values so that test results from different thromboplastins and coagulation 
analyzers would be equivalent.  Under the INR system, the thromboplastin is assigned an international sensitivity index (ISI) value.  
The ISI indicates the relative sensitivity of the thromboplastin compared to an international reference thromboplastin.  The ISI, the 
patient’s PT, and the mean normal PT, which is a value derived in each laboratory by averaging at least 20 normal individuals, are 
used to calculate the INR.  
The targeted INR value for patients being treated for acute myocardial infarction, atrial fibrillation, venous thromboembolism, and 
bioprosthetic cardiac valves is typically 2.5.  The INR goal for patients with mechanical valves or for patients with lupus inhibitor and 
recurrent thromboembolism is typically 3.0.  Some patients may experience spontaneous bleeding during warfarin therapy.  Such 
patients typically have one or more of the following characteristics: age greater than 75 years, poorly controlled hypertension, liver 
disease, poor drug compliance, presence of bleeding lesions or disorders, concomitant use of nonsteroidal anti-inflammatory drugs 
(NSAIDS), and instability of INR control or INR greater than 3.0.5-7  In general, the risk of major bleeding episodes in patients treated 
with warfarin is thought to be related to the degree of anticoagulation.  Studies in patients with atrial fibrillation indicate that risk of 
bleeding increases substantially at INR values above 4.0.8,9 
When planning elective surgery, the surgeon must consider the alternatives of maintenance, modification, or discontinuation of 
anticoagulation.  It is of singular importance to evaluate the rationale for which the patient is being anticoagulated.  Patients at low risk 
of thromboembolic disease include those with a history of deep vein thrombosis (DVT) after more than 3 months without high risk 
factors, nonvalvular atrial fibrillation, or cardiomyopathy without atrial fibrillation.  Those at high risk of thromboembolic disease are 
patients with hypercoagulable states, mechanical valves, DVT with high risk factors or of recent history, or atrial fibrillation with high 
risk factors such as a history of prior thromboembolic episodes, heart failure, left ventricular dysfunction, mitral stenosis, thyroid 
disease, or age greater than 75 years with a history of diabetes or hypertension.10,11  The consequences of arterial thromboembolism 
are much more serious than those of the venous circulation, with 20% of episodes being fatal and 40% causing permanent 
disability.12,13   
Commercially available warfarin has a biologic half-life of 36 to 42 hours.  After cessation of oral warfarin, it typically requires 
several days for the INR to fall below 2.0.  One study prospectively evaluated 22 patients with a baseline INR of 2.6, in whom it was 
considered safe to discontinue warfarin therapy.14  The INR fell to 1.6 at 2.7 days and 1.2 at 4.7 days.  Following reinstitution of 
warfarin therapy, it takes approximately 3 to 4 days for the INR to rise above 2.0.  It is therefore estimated that if warfarin is withheld 
for 4 days prior to surgery and treatment is started as soon as possible following the surgical procedure, the patient will have a 
subtherapeutic INR for approximately 2 days before surgery and 2 days postoperatively.14-16 
There is no current consensus regarding the management of patients undergoing elective surgery while on long-term 
anticoagulation therapy.  The primary concern associated with discontinuation of anticoagulation prior to surgery is the increased risk 
of thromboembolism and cerebrovascular accident.  There is also concern regarding life-threatening rebound hypercoagulability 
following the abrupt cessation of anticoagulation.17-19  These concerns need to be weighed against the potential for hemorrhagic 
complications that may occur during or following surgery.   
Maintenance of anticoagulation has been shown to be safe in elective, nonocular surgical procedures.  In one series of patients 
undergoing cholecystectomy or gastric resection, there was no difference in blood loss between patients that were anticoagulated and 
those that were not.20  Anticoagulation has also been shown to be safe in patients undergoing dental extraction.21,22   
Kallio and associates23 studied the risk of hemorrhagic complications related to ocular anesthesia.  In a series of 1,383 patients 
undergoing intraocular surgery, 482 patients were using preoperative acetylsalicylic acid, 260 patients were taking NSAIDs, and 76 
patients were on warfarin.  This study showed no predisposition to hemorrhage associated with either retrobulbar or peribulbar 
anesthesia. 
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Current reports concerning the risk of hemorrhagic ocular complications with ophthalmic surgery in patients on anticoagulation are 
mixed. Some studies have found an increased risk of bleeding,24-27 whereas others have not.16,23,28-38  Most published reports suggest 
that warfarin therapy may be safe in patients undergoing cataract or oculoplastic surgery.16,23,28-38  Katz and associates, 31 in a review of 
19,283 cataract surgeries, identified 752 patients on warfarin therapy;  10.5% of these patients were advised to stop anticoagulation 
therapy prior to surgery.  In this study, there were no ocular hemorrhages among warfarin users, whether or not treatment was 
discontinued within 4 days of surgery.  In a series of 41 anticoagulated patients undergoing a range of 50 ophthalmic procedures, 
McCormack and colleagues28 found no significant hemorrhagic complications associated with anesthesia or surgery.  Gainey and 
coworkers24 also reviewed the outcome of 50 patients on warfarin therapy undergoing ocular surgery.  There was no significant 
difference in hemorrhagic complications observed among patients in whom warfarin therapy was continued and those in whom it was 
discontinued.  Jonas and associates,38 in a review of patients undergoing cataract surgery, found 21 patients on systemic 
anticoagulation with warfarin and found no increased risk of intraoperative or postoperative hemorrhage. 
There is limited existing literature regarding the safety of vitreoretinal procedures in patients in whom aspirin therapy or warfarin 
anticoagulation is maintained.  Flaxel and Blach39 described three patients treated with aspirin who experienced intraocular 
hemorrhage during vitreoretinal surgery.  In McCormack and associate’s series28 of 50 ophthalmic procedures, there were no 
hemorrhagic complications among the eight patients who underwent vitreoretinal surgery.  In a series of 50 patients receiving warfarin 
anticoagulation, Gainey and coworkers24 described six who underwent vitreoretinal procedures.  None of these patients had 
hemorrhagic complications.  However, Narendran and Williamson25 described seven patients who underwent vitreoretinal surgery 
while on anticoagulation.  Two of the seven suffered hemorrhagic complications, including one postoperative hemorrhagic choroidal 
detachment and one recurrent vitreous hemorrhage.  Narendran and Williamson25 concluded that warfarin anticoagulation was 
associated with an increased risk of hemorrhagic complications.  McDonald’s review of vitreoretinal surgery in patients on 
anticoagulation included 12 patients whose INR was 2.0 or greater (McDonald HR,  Retina Subspecialty Day 2003,  Abstract). One 
patient in this group suffered a subretinal hemorrhage during external drainage of subretinal fluid in the course of scleral buckling.  
Our study describes 54 patients who underwent 57 vitreoretinal procedures.  We found 35 patients who had INRs ranging from 1.2 
to 1.9, values that we considered subtherapeutic.  These 35 patients underwent 38 vitreoretinal procedures.  There were no 
intraoperative hemorrhagic complications.  In this group, two procedures (5%), in patients with INR values of 1.28 and 1.41, were 
associated with postoperative hemorrhage but required no additional surgery.  There were 19 patients with an INR value of 2.0 or 
greater who underwent 19 vitreoretinal procedures.  In this group, there were no intraoperative hemorrhagic complications. Two 
patients (11%), with INR values of 2.68 and 2.69, experienced postoperative hemorrhagic complications.  Both resolved 
spontaneously, requiring no additional surgery.  It is noteworthy that among the four patients with postoperative hemorrhagic 
complications, one had an elevated PTT value equal to 55.3 seconds and another was on concurrent aspirin therapy. 
Surgical technique for the patients in our study was identical to that used in patients who were not anticoagulated.  Meticulous 
bipolar diathermy was used to control bleeding during the initial exposure of the globe and during isolation of muscles in those 
patients undergoing buckling in addition to vitrectomy.  Scleral buckling procedures, especially those involving encirclage, require 
considerably more dissection with the potential for greater intraoperative bleeding.  However, unusual degrees of bleeding were not 
encountered during such dissections in these patients.  Prior to performing sclerotomies in the course of vitrectomy, episcleral vessels 
were diathermized.  Dissection of retinal fibrovascular proliferation was accompanied by intraocular diathermy.  It is possible that the 
postoperative hemorrhages seen in our patients were related to bleeding from sclerotomies or incisions into fibrovascular proliferative 
stalks.  However, no such bleeding occurred intraoperatively.   
Subretinal hemorrhage is a known complication of external drainage during scleral buckling procedures and may be attributable to 
a variety of factors, including puncture or laceration of choroidal vessels, as well as acute hypotony.  McDonald described one patient 
who developed subretinal hemorrhage during external drainage of subretinal fluid in the course of a scleral buckling procedure 
(McDonald HR,  Retina Subspecialty Day 2003,  Abstract).  
In the series presented herein, three patients with INR values of 1.2 to 1.9 underwent scleral buckling as a component of their 
vitreoretinal surgery; among those patients considered to have therapeutic levels of anticoagulation with INR greater than 2.0, five 
patients underwent scleral buckling in addition to vitrectomy.  It is important to note that external drainage was not attempted in any 
of the patients in this series who underwent buckling in conjunction with vitrectomy.  Instead, flattening of the retina was achieved 
with internal drainage and gas tamponade.  In our series, we experienced no intraoperative bleeding associated with these measures, 
and no postoperative hemorrhagic complications occurred in patients who underwent scleral buckling in conjunction with vitrectomy. 
In this series, in which 13 procedures were performed using general anesthesia and 44 using local infiltration of anesthesia with 
MAC, no anesthetic complications were encountered.  The technique we employ for administration of local infiltrative anesthesia 
consists of topical anesthesia followed by intravenous sedation.  Using a sharp 30-gauge needle, a subconjunctival injection results in 
elevation of a bleb of conjunctiva.  A small limbal incision can then be made to allow blunt dissection of Tenon’s  capsule through 
which a blunt-tipped curved cannula may be passed into the sub-Tenon’s space.  Infiltration of local anesthesia can then be 
accomplished, resulting in adequate anesthesia and akinesia for vitreoretinal surgery, thus avoiding potential hazards of hemorrhage 
associated with retrobulbar injections. 
The use of aspirin and NSAIDS has been postulated to increase the risk of bleeding in warfarin-treated patients by multiple 
mechanisms, including interference with platelet function through inhibition of cyclooxygenase-I (COX-I).40  The use of COX-II 
selective NSAIDS may lead to fewer complications, because these agents do not interfere with platelet function.  None of the patients 
in our series using COX-II therapy developed new postoperative hemorrhagic complications. 
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In conclusion, this is the single largest report to date of vitreoretinal surgical procedures in patients who had therapeutic levels of 
warfarin anticoagulation.  The study is limited in that it was conducted in a retrospective fashion, the sample size is small, and there 
was no control group.  Furthermore, we were unable to collect data regarding whether patients in this study ingested herbal 
supplements known to have an anticoagulation effect or to potentiate the effects of warfarin anticoagulation.41  However, it would 
seem logical that the concomitant use of such supplements would increase, rather than decrease, the risk of intraoperative or 
postoperative hemorrhage and would be unlikely to skew results toward fewer hemorrhagic complications.   
Our findings suggest that many patients may safely undergo vitreoretinal surgery while maintaining therapeutic levels of warfarin 
anticoagulation.  In our series, no patient suffered an intraoperative hemorrhagic complication.  Four eyes (7.0%) experienced 
postoperative hemorrhages that resolved spontaneously without persistent visual sequelae or the need for supplemental surgery.  The 
ultimate visual results for patients in this series were quite favorable (Figures 1 and 2).  On the basis of these findings, when caring for 
patients in whom the systemic risks of cessation of anticoagulation may be substantial, ophthalmic surgeons may wish to consider 
undertaking vitreoretinal procedures while maintaining anticoagulation therapy.  Anesthetic and surgical techniques may need to be 
modified or adjusted to avoid maneuvers thought to increase the risk of hemorrhage.  The decision to withhold, modify, or continue 
anticoagulation should be individualized, taking into consideration the patient’s medical history, systemic findings, and the specific 
surgical procedure required for management of the underlying vitreoretinal abnormality.  Consultation with the physician responsible 
for monitoring the patient’s anticoagulation is prudent.  Finally, such patients must be fully informed of the risks involved with either 
maintenance or discontinuation of anticoagulation therapy. 
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PEER DISCUSSION 
DR PAUL E TORNAMBE: ‘If you prick us, do we not bleed?’ (Shylock, Merchant of Venice, Act III Scene I). If Shylock needed 
vitreoretinal surgery and was taking warfarin at the time, Dr. Grand apparently would have said, “No, if we prick you, you probably 
will not bleed.” Drs. Dayani and Grand provides us the largest series reported on this subject. Common sense suggests that stopping a 
drug that prevents blood from clotting before surgery should likely decrease the chances of intraoperative and postoperative bleeding. 
This paper provides good evidence that common sense does not always provide the correct answer. Sometimes the observation 
precedes the explanation. Perhaps the explanation lies in the incision size which is more like a puncture than a laceration. Perhaps the 
explanation lies in the vascularity of the tissue. Perhaps there is a difference between intravascular clotting, which prevents clots from 
forming on heart valves; and, extravascular clotting, which prevents a clot from plugging a vessel. Whatever the reason, this paper 
decisively shows that, if proper precautions are taken, it is not necessary to stop warfarin before vitreoretinal surgery.  
The weakness of the study is its retrospective nature and relatively small sample size, but the remainder of the design is good. No 
patients were excluded, even those taking other drugs such as aspirin, non-steroidal anti-inflammatory drugs, or Plavix.  There is 
adequate follow up, and grouping by INR strengthens the argument for the minor bleeding problems, which occurred in both 
adequately anti-coagulated and marginally anti-coagulated eyes. 
Medicolegally, you’re damned if you do and damned if you don’t! The surgeon might be medicolegally exposed if the 
anticoagulants are stopped before surgery and the patient has an embolic event. On the other hand, there may be similar exposure if 
the drugs are not stopped and the patient experiences an expulsive hemorrhage.  
It appears that warfarin does not have to be stopped before vitreoretinal surgery, but issues must be addressed preoperatively. 
There must be good communication with the patient’s medical doctors. The patient must be responsible and the INR less than three. 
Blood pressure must be controlled, there should be no liver disease, and the intraoperative necessity of other anticoagulant medicines 
must be assessed. 
There must be a surgical plan. If general anesthesia is not an option, a peribulbar injection with a blunt needle is advisable. If 
vessels are transected they should be cauterized either before or promptly after the dissection. If subretinal fluid drainage is necessary, 
it should be performed internally. To minimize the chances of choroidal detachment, hypotony should be avoided, and the vortex 
veins should not be compromised. 
This paper brings important information to the vitreoretinal surgeon. Stopping warfarin may have life threatening implications. 
Although most of us consider the body an appendage of the eye, these circumstances mandate we consider the total patient’s well 
being.  
If you prick us, we may not bleed, but if you take a pound of flesh, we probably will! 
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DR MICHAEL H. GOLDBAUM.: One explanation for the benign outcome of the bleeding may be because you have a closed system 
that creates a tamponade as the bleeding causes the pressure to go up inside the eye. An eye more at risk may be one with a 
functioning bleb, which more approximates an open eye, where bleeding can expand without pressure tamponade. 
DR ALLAN J. FLACH: It’s a shame you didn’t have data on Ginkgo Biloba and Vitamin E because that might be the explanation for 
the bleeding. It appeared in the sub-therapeutic group that there were an unusually large number of general anesthesias given. I 
wonder, since there were two hemorrhages there, could the hemorrhages have been related to the anesthesia or subsequent bucking or 
something specific to that approach to anesthesia? 
DR DENNIS M. ROBERTSON: Ginkgo, garlic, ginseng, and ginger are four herbals pretty easy to remember because they all start 
with “g”, but they all inhibit platelet aggregation.  So, your might consider that in your patient history. 
DR M. GILBERT GRAND : Dr Tornambe brings up the issue of relative risk. You have a relative risk of leaving your patient on 
anticoagulation, and taking the risk of anesthetic-related or surgically related hemorrhage, versus the risk of discontinuation of 
anticoagulation. Your decision depends greatly on the underlying disease process and the duration of that process. For instance, many 
patients who are anticoagulated have been on anticoagulants for many years, yet do not have a current reason for maintaining this 
anticoagulation. For example, they may have had a deep-vein thrombosis 15 years ago and warfarin has been maintained through this 
time. Or they may have had an episode of angina, for which they have been anticoagulated. There are some people for whom the risk 
of discontinuation is relatively minor. On the other hand, arterial embolisms are a much greater concern than are venous embolisms. 
Patients who have mechanical heart valves have a much greater risk of having a serious life-threatening condition occur following 
cessation of anticoagulation. The point that Dr. Tornambe made about communication with the patient’s primary care doctor is a very 
valid one and should be the very first step. 
The point of pricking or cutting was brought up. The reason I would have expected more bleeding was the fact that we are making 
three incisions through the so-called vascular tunic of the eye. At the time that we initially make those incisions, the globe is 
hypotonous so there is not a really good tamponade effect. But despite those incisions, we have not experienced bleeding in the course 
of vitrectomy.  
The issue of the medical-legal aspects is a very critical one. There has been a recent symposium given by OMIC and among the 
cases that were presented was one in which the ophthalmologist was sued for administering the retrobulbar block in a patient on 
coumadin anticoagulation. There was a judgment in favor of the plaintiff in that case. The older literature indicates that 
anticoagulation should be modified or discontinued prior to embarking on ocular surgery. But a more recent appraisal of the literature 
shows that certainly cataract surgery can be done safely despite anticoagulation. Our study has shown that the risk of bleeding during 
vitreoretinal surgery, while not zero, is smaller than one might have anticipated. Thus it is a reasonable option, made with the patient’s 
internist and the patient, to embark on a course of maintaining coagulation.  
The reasons for the use of Avastin continue to expand. Like Dr. Tornambe, we have used Avastin in pre-vitrectomy treatment of 
diabetics with severely aggressive vascular proliferation, both those who have iris neovascularization as well as those with 
fibrovascular proliferation in the retina.  Like Dr. Tornambe has shown, within a matter of three or four days, the vascularity regresses 
dramatically. . I think this does make for safer intraocular surgery. 
As far as the tamponade effect that Dr. Goldbaum raised, there is some tamponade as we do our cases, sometimes with pressures in 
the 30s. Tamponade may be the reason that we can do intraocular injections, such as Kenalog or Avastin, without much risk of 
bleeding. We have not specifically looked at needle perforation into the globe for these reasons in patients who are anticoagulated, but 
I suspect the risk of bleeding is small since there is a period of ocular hypertension related to the immediate injection. 
As far as use of nutritional supplements, I do not have that information. 
